Cargando…

Activation of the Peroxisome Proliferator-Activated Receptors (PPAR-α/γ) and the Fatty Acid Metabolizing Enzyme Protein CPT1A by Camel Milk Treatment Counteracts the High-Fat Diet-Induced Nonalcoholic Fatty Liver Disease

Camel milk (CM) has a unique composition rich in antioxidants, trace elements, immunoglobulins, insulin, and insulin-like proteins. Treatment by CM demonstrated protective effects against nonalcoholic fatty liver disease (NAFLD) induced by a high-fat cholesterol-rich diet (HFD-C) in rats. CM dampene...

Descripción completa

Detalles Bibliográficos
Autores principales:	AlNafea, Haifa M., Korish, Aida A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2021
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8285205/ https://www.ncbi.nlm.nih.gov/pubmed/34306045 http://dx.doi.org/10.1155/2021/5558731

Ejemplares similares

The interplay between hypovitaminosis D and the immune dysfunction in the arteriovenous thrombotic complications of the sever coronavirus disease 2019 (COVID-19) infection
por: AlNafea, Haifa M., et al.
Publicado: (2023)

Angiotensin-I Converting Enzyme Inhibition and Antioxidant Activity of Papain-Hydrolyzed Camel Whey Protein and Its Hepato-Renal Protective Effects in Thioacetamide-Induced Toxicity
por: Osman, Ali, et al.
Publicado: (2021)

Camel milk ameliorates steatohepatitis, insulin resistance and lipid peroxidation in experimental non-alcoholic fatty liver disease
por: Korish, Aida A, et al.
Publicado: (2013)

Update on Pparγ and Nonalcoholic Fatty Liver Disease
por: Ables, Gene P.
Publicado: (2012)

Medium Chain Fatty Acids Are Selective Peroxisome Proliferator Activated Receptor (PPAR) γ Activators and Pan-PPAR Partial Agonists
por: Liberato, Marcelo Vizoná, et al.
Publicado: (2012)

Peroxisome Proliferator-Activated Receptors Associated with Nonalcoholic Fatty Liver Disease
por: Wang, Nan, et al.
Publicado: (2017)

Peroxisome Proliferator-Activated Receptor-γ as a Target and Regulator of Epigenetic Mechanisms in Nonalcoholic Fatty Liver Disease
por: Zaiou, Mohamed
Publicado: (2023)

Regulation of PPAR-γ activity in lipid-laden hepatocytes affects macrophage polarization and inflammation in nonalcoholic fatty liver disease
por: Li, Xiao-Yun, et al.
Publicado: (2022)

Omega 3 polyunsaturated fatty acid improves spatial learning and hippocampal Peroxisome Proliferator Activated Receptors (PPARα and PPARγ) gene expression in rats
por: Hajjar, Toktam, et al.
Publicado: (2012)

Underexpression of peroxisome proliferator-activated receptor (PPAR)γ in PAX8/PPARγ-negative thyroid tumours
por: Marques, A R, et al.
Publicado: (2004)

Expression of peroxisome proliferator-activated receptor (PPAR)γ in gastric cancer and inhibitory effects of PPARγ agonists
por: Sato, H, et al.
Publicado: (2000)

Oleamide activates peroxisome proliferator-activated receptor gamma (PPARγ) in vitro
por: Alexander, Stephen PH, et al.
Publicado: (2012)

Intervening TNF-α via PPARγ with Gegenqinlian Decoction in Experimental Nonalcoholic Fatty Liver Disease
por: Wang, Yun-liang, et al.
Publicado: (2015)

Functions of Peroxisome Proliferator-Activated Receptor Gamma (PPARγ) in Gynecologic Disorders
por: Ren, Ping, et al.
Publicado: (2015)

Mechanisms Mediating the Regulation of Peroxisomal Fatty Acid Beta-Oxidation by PPARα
por: Tahri-Joutey, Mounia, et al.
Publicado: (2021)

Molecular recognition of nitrated fatty acids by PPARγ
por: Li, Yong, et al.
Publicado: (2008)

Omega-3 Fatty Acids and PPARγ in Cancer
por: Edwards, Iris J., et al.
Publicado: (2008)

A role of peroxisome proliferator‐activated receptor γ in non‐alcoholic fatty liver disease
por: Skat‐Rørdam, Josephine, et al.
Publicado: (2019)

Peroxisome proliferator‐activated receptor gamma (PPARγ) regulates lactase expression and activity in the gut
por: Fumery, Mathurin, et al.
Publicado: (2017)

Peroxisome Proliferator-Activated Receptor Genetic Polymorphisms and Nonalcoholic Fatty Liver Disease: Any Role in Disease Susceptibility?
por: Dongiovanni, Paola, et al.
Publicado: (2013)

Sijunzi, Lizhong, and Fuzilizhong Decoction Alleviate Nonalcoholic Fatty Liver Disease through Activation of PPAR Pathway
por: Yang, Jiayao, et al.
Publicado: (2020)

Peroxisome Proliferator-Activated Receptors (PPAR)γ Agonists as Master Modulators of Tumor Tissue
por: Heudobler, Daniel, et al.
Publicado: (2018)

A Novel Splicing Variant of Peroxisome Proliferator-Activated Receptor-γ (Pparγ1sv) Cooperatively Regulates Adipocyte Differentiation with Pparγ2
por: Takenaka, Yasuhiro, et al.
Publicado: (2013)

Different skeletal effects of the peroxisome proliferator activated receptor (PPAR)α agonist fenofibrate and the PPARγ agonist pioglitazone
por: Syversen, Unni, et al.
Publicado: (2009)

The involvement of peroxisome proliferator-activated receptor gamma (PPARγ) in anti-inflammatory activity of N-stearoylethanolamine
por: Kosiakova, H., et al.
Publicado: (2022)

Intestinal peroxisome proliferator‐activated receptor α‐fatty acid‐binding protein 1 axis modulates nonalcoholic steatohepatitis
por: Yan, Tingting, et al.
Publicado: (2023)

Quantitative proteomics reveals Polygonum perfoliatum L. ameliorates hepatic steatosis by promoting PPARs/CPT1A/CPT2-mediated fatty acid β-oxidation
por: Liu, Guanjie, et al.
Publicado: (2023)

New Target Genes for the Peroxisome Proliferator-Activated Receptor-γ (PPARγ) Antitumour Activity: Perspectives from the Insulin Receptor
por: Foti, Daniela P., et al.
Publicado: (2009)

Activation of the peroxisome proliferator activated receptor γ counteracts sepsis-induced T-cell cytotoxicity towards alloantigenic target cells
por: Knethen, A von, et al.
Publicado: (2014)

Two Isomeric C16 Oxo-Fatty Acids from the Diatom Chaetoceros karianus Show Dual Agonist Activity towards Human Peroxisome Proliferator-Activated Receptors (PPARs) α/γ
por: Moldes-Anaya, Angel, et al.
Publicado: (2017)

Natural Compounds for Counteracting Nonalcoholic Fatty Liver Disease (NAFLD): Advantages and Limitations of the Suggested Candidates
por: Salvoza, Noel, et al.
Publicado: (2022)

Triflumizole Is an Obesogen in Mice that Acts through Peroxisome Proliferator Activated Receptor Gamma (PPARγ)
por: Li, Xia, et al.
Publicado: (2012)

Natural product agonists of peroxisome proliferator-activated receptor gamma (PPARγ): a review
por: Wang, Limei, et al.
Publicado: (2014)

Ligand Binding Reduces SUMOylation of the Peroxisome Proliferator-activated Receptor γ (PPARγ) Activation Function 1 (AF1) Domain
por: Diezko, Rolf, et al.
Publicado: (2013)

Peroxisome proliferator-activated receptors (PPARα, PPARγ and PPARβ/δ) gene expression profile on ram spermatozoa and their relation to the sperm motility
por: Kadivar, Ali, et al.
Publicado: (2016)

Role of Apolipoprotein A1 in PPAR Signaling Pathway for Nonalcoholic Fatty Liver Disease
por: Chen, Changxi, et al.
Publicado: (2022)

PPARα-mediated peroxisome induction compensates PPARγ-deficiency in bronchiolar club cells
por: Karnati, Srikanth, et al.
Publicado: (2018)

Time-Dependent Vascular Effects of Endocannabinoids Mediated by Peroxisome Proliferator-Activated Receptor Gamma (PPARγ)
por: O'Sullivan, Saoirse E., et al.
Publicado: (2009)

Is peroxisome proliferator-activated receptor gamma (PPARγ) a therapeutic target for the treatment of pulmonary hypertension?
por: Green, David E., et al.
Publicado: (2011)

Molecular Modeling of Allosteric Site of Isoform-Specific Inhibition of the Peroxisome Proliferator-Activated Receptor PPARγ
por: Almahmoud, Suliman, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_r6d25vqrhdllarighl5fiq8coh